论文部分内容阅读
从１９８５年５月～１９８９年５月，作者采用单克隆抗体ＯＣ１２５，以放射免疫固相测定法进行检测人血清ＣＡ１２５抗原。测定结果，确定在本文研究中的血清ＣＡ１２５正常值为６５Ｕ／ｍｌ，≤６５Ｕ／ｍｌ为阴性，＞６５Ｕ／ｍｌ为阳性。卵巢上皮性癌患者的血清ＣＡ１２５水平８１．５％（７５／９２）为阳性，明显高于对照人群的２．５％，其中浆液性癌阳性率高达９３．２％（４１／４４）．根据ＣＡ１２５数值的动态变化来观察对评定疗效、预示复发及指导选择二探术等方面的临床意义，ＣＡ１２５阳性的病例不需要接受二探术，ＣＡ１２５水平与肿瘤变化的符合率达９２．９％。这充分证明ＣＡ１２５＞６５Ｕ／ｍｌ水平，肿瘤病灶＞２ｃｍ者，对化疗的反应差，预后也差。
From May 1985 to May 1989, the authors used a monoclonal antibody OC125 to detect human serum CA125 antigen by radioimmunoassay. Determination of the results to determine the normal serum CA125 in this study was 65U / ml, ≤ 65U / ml was negative,> 65U / ml was positive. The serum CA125 level in patients with epithelial ovarian cancer was 81.5% (75/92), which was significantly higher than 2.5% of the control population. The positive rate of serous carcinoma was 93.2% (41/44). According to the dynamic changes of CA125 value to observe the evaluation of the curative effect, predict the recurrence and guide the choice of second-hand clinical significance, CA125-positive cases do not need to accept the second probe, CA125 levels and tumor changes in line with the rate of 92.9% . This fully proves CA125> 65U / ml level, tumor lesions> 2cm, the response to chemotherapy is poor, the prognosis is poor.